Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

Immune checkpoint (IC) inhibitor drug holidays are safe in patients with metastatic melanoma who achieve an objective ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

We see the gap between the survival curves continue to widen, which is exactly what we want to see in lung cancer treatment ...

Discover the latest findings on transplantation outcomes in Myelodysplastic Syndrome and Acute Myeloid Leukaemia from EBMT ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...